Payment & Shipping Terms:
|Application:||Research Chemical||Package:||Aluminum Foil Bag|
|Port:||Beijing, Shenzhen, Tianjin, HK||Storage:||Kept In A Cool|
Imiquimod CAS 99011-02-6 Pharmaceutical Grade,
white powder chemical
Imiquimod is a kind of imidozoquinoline amine-class interleukin agonist developed by the 3M Pharmaceuticals Company (US), belonging to the drug for the treatment of genital warts. Upon being applied to the mice skin, it can induce the cytokinesis and produce α-interferon, tumor necrosis factor and many kinds of interleukins. Clinically it can be used as the immunomodulators in the treatment of adult genital and perianal warts with convenient application, well tolerance and unique mechanism of action which makes it be the first-choice drug for treatment of genital warts. In addition, there are reports that imiquimod can be used for treating viral skin diseases including common warts, flat warts, molluscum and herpes simplex virus. It can also be effective in treating basal cell carcinoma, Bowen's disease, Bowen papulosis, actinic keratosis, and skin tum.
Imiquimod can be used for the treatment of adult external genital and perianal genital warts at 3 times per week. Just before sleep, first apply the product evenly in a thin layer on the surface of the wart and gently massage until the product is completely absorbed.
The position of the medication should not be packeted and should be maintained for 6 to 10 hours, and then wash with a neutral soap and clean water for clearing the drugs in the administration site. Wash your hands before and after treatment.
250 mg of cream can be applied to 20cm2 of wart. Avoid excessive application of the drug. Patients should continue the treatment until the wart is completely cleared. Wart can be cleared within 2-4 week at the fastest speed and can be generally cleared within 8 to 12 weeks. The medication should be not more than 16 weeks.
After the treatment, patients with mild erythema locally who does not have to be discontinued for drug; if the patients feel general malaise or get local skin reactions (edema, erosion, pain, etc.), the drug should be discontinued. Only when the reaction is alleviated can they continue the medication.
1kg/2kg/5kg aluminum foil, 10kg/25kg drum
|Description||White crystalline powder|
|Solubility||Tiny dissolve in 0.1mol/L Hcl|
|Assay(on dried basis)||98~101%|
|Related substances||1.0% Max|
|Heavy metals||10ppm Max|
|Loss on drying||0.5% Max|
|Burning residue||0.2% Max|
Contact Person: July